The use of the calcitonin gene-related peptide (CGRP) antagonist rimegepant 75 mg for 52 weeks showed a favorable safety profile and sustained benefits for migraine prevention in a new open-label ...
Author(s)Ashina M, Tepper S, Brandes JL, et al. Efficacy, safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results